Raymond James & Associates Gilead Sciences, Inc. Transaction History

Raymond James & Associates

$146 Billion
Q1 2024

A detailed history of Raymond James & Associates transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 2,031,209 shares of GILD stock, worth $139 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

2,031,209

Previous 2,483,440 18.21%

Holding current value

$139 Million

Previous $201 Million 26.04%

% of portfolio

0.1%

Previous 0.15%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 22, 2024	SELL	$71.58 - $87.29 $32.4 Million - $39.5 Million	-452,231 Reduced 18.21%	2,031,209 $149 Million
Q4 2023 Jan 16, 2024	BUY	$73.27 - $83.09 $11.6 Million - $13.2 Million	158,346 Added 6.81%	2,483,440 $201 Million
Q3 2023 Oct 24, 2023	BUY	$73.94 - $80.67 $20.5 Million - $22.3 Million	276,676 Added 13.51%	2,325,094 $174 Million
Q2 2023 Jul 25, 2023	SELL	$76.01 - $86.7 $24.6 Million - $28.1 Million	-323,605 Reduced 13.64%	2,048,418 $158 Million
Q1 2023 Apr 14, 2023	SELL	$77.31 - $88.08 $35.1 Million - $39.9 Million	-453,373 Reduced 16.05%	2,372,023 $197 Million

Q4 2022 Feb 08, 2023	SELL	$62.32 - $89.47 $10 Million - $14.4 Million	-160,462 Reduced 5.37%	2,825,396 $243 Million
Q3 2022 Oct 25, 2022	BUY	$59.54 - $68.01 $5.03 Million - $5.74 Million	84,400 Added 2.91%	2,985,858 $184 Million
Q2 2022 Aug 12, 2022	BUY	$57.72 - $65.01 $17 Million - $19.2 Million	295,348 Added 11.33%	2,901,458 $179 Million
Q1 2022 May 11, 2022	BUY	$57.92 - $72.58 $6.12 Million - $7.67 Million	105,652 Added 4.23%	2,606,110 $155 Million
Q4 2021 Feb 08, 2022	SELL	$64.88 - $73.64 $4.88 Million - $5.54 Million	-75,175 Reduced 2.92%	2,500,458 $182 Million
Q3 2021 Nov 02, 2021	SELL	$67.69 - $73.03 $2.48 Million - $2.68 Million	-36,645 Reduced 1.4%	2,575,633 $180 Million
Q2 2021 Aug 11, 2021	BUY	$63.47 - $69.35 $8.23 Million - $9 Million	129,741 Added 5.23%	2,612,278 $180 Million
Q1 2021 May 14, 2021	BUY	$60.0 - $68.46 $11.1 Million - $12.7 Million	185,705 Added 8.09%	2,482,537 $160 Million
Q4 2020 Feb 12, 2021	BUY	$56.65 - $64.55 $4.76 Million - $5.42 Million	83,988 Added 3.8%	2,296,832 $134 Million
Q3 2020 Nov 04, 2020	BUY	$62.1 - $78.08 $33.6 Million - $42.2 Million	540,455 Added 32.32%	2,212,844 $140 Million
Q2 2020 Jul 28, 2020	SELL	$72.34 - $84.0 $44 Million - $51.1 Million	-607,851 Reduced 26.66%	1,672,389 $129 Million
Q1 2020 Apr 21, 2020	SELL	$62.63 - $80.22 $20.7 Million - $26.5 Million	-330,677 Reduced 12.67%	2,280,240 $170 Million
Q4 2019 Feb 12, 2020	SELL	$61.62 - $67.78 $5.09 Million - $5.6 Million	-82,573 Reduced 3.07%	2,610,917 $170 Million
Q3 2019 Nov 07, 2019	BUY	$62.51 - $69.0 $105 Million - $116 Million	1,674,157 Added 164.24%	2,693,490 $171 Million
Q2 2019 Aug 06, 2019	SELL	$61.87 - $69.38 $671,289 - $752,773	-10,850 Reduced 1.05%	1,019,333 $68.9 Million
Q1 2019 May 06, 2019	BUY	$62.53 - $70.05 $9.6 Million - $10.8 Million	153,595 Added 17.52%	1,030,183 $67 Million
Q4 2018 Feb 11, 2019	SELL	$60.54 - $79.0 $2.34 Million - $3.05 Million	-38,590 Reduced 4.22%	876,588 $54.8 Million
Q3 2018 Nov 14, 2018	BUY	$71.28 - $78.92 $12 Million - $13.3 Million	167,901 Added 22.47%	915,178 $70.7 Million
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $5.51 Million - $6.42 Million	-84,849 Reduced 10.2%	747,277 $52.9 Million
Q1 2018 May 14, 2018	SELL	$72.84 - $88.8 $148,520 - $181,063	-2,039 Reduced 0.24%	832,126 $62.7 Million
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $9.62 Million - $11.3 Million	-135,254 Reduced 13.95%	834,165 $59.8 Million
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $3.15 Million - $3.74 Million	43,700 Added 4.72%	969,419 $78.5 Million
Q2 2017 Aug 14, 2017	BUY	N/A	925,719	925,719 $65.5 Million

Others Institutions Holding GILD

# of Institutions

1,884

Shares Held

Call Options Held

8.71M

Put Options Held

8.02M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $86B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Gilead Sciences, Inc. Transaction History